Compare Neurocrine Biosciences Inc (NBIX) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Phillips 66 — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Phillips 66 trades at $212.01 (market cap $83.72B). The key difference: Phillips 66 is far larger — about 4.8× Neurocrine Biosciences Inc's market cap, and Phillips 66 pays a 2.43% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | PSX | |
|---|---|---|
Market Cap | $17.40B | $83.72B |
Sector | Health | Energy |
52-Week High | $180.55 | $208.80 |
52-Week Low | $123.10 | $118.37 |
Enterprise Value | $16.49B | $105.69B |
Dividend Yield | — | 2.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Phillips 66 (PSX) trades at $212.27, up 2.62% today, with a bullish technical signal and strong analyst support. Recent earnings beats, including Q1 2026's positive surprise, highlight operational strength amid volatile energy markets. The stock benefits from robust refining margins and disciplined capital returns, including a $1.27 quarterly dividend. Valuation metrics like a P/E of 20.63 and P/S of 0.63 suggest relative affordability compared to sector peers.
Outlook remains positive due to tight fuel markets and efficient refining operations, though risks include oil price volatility and declining revenue trends. With 57% of analysts rating it a buy and a consensus price target of $201.50, the stock offers upside potential, but investors should monitor debt levels and macroeconomic pressures on energy demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
